Figure S1. Quantitative abundances of the proteins involved in mitochondrial fusion and fission and mitoribosomes in brain proteomes of early onset AD (log2 (115/114)), late onset AD (log2 (117/116)) and healthy aging subjects (log2 (116/114)). A) iTRAQ quantitative ratios of proteins involved in mitochondrial fusion and fission, B) and C) iTRAQ quantitative proteins of mitoribosomes. (DOCX 144 kb
Figure S4. TMT Network Modules Associated with Disease State or AD Pathology. (A-F) TMT network modu...
Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asympt...
Table S1. Sample List. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; M...
Table S1. iTRAQ quantified human brain proteome of AD individuals and their age-matched control. The...
Table S3. iTRAQ-quantified Mitochondrial proteins with log2 iTRAQ ratio. (XLSX 107 kb
Table S4. Proteins identified in purified mitochondria from each individuals. The data presented is ...
Table S2. iTRAQ quantified human brain proteome of AD individuals and their age-matched control with...
Table S4. Pathway analysis of proteins differentially increased in 5xFAD (vs. WT) microglia. (XLSX 1...
Figure S1. SDS-PAGE of Brain Homogenates. Dorsolateral prefrontal cortex (DLPFC) brain tissue homoge...
A. Percentage coefficient of variation of calculated iTRAQ ratios. Less than 5 % of protein ratios i...
Table S1. Demographic and neuropathological data of human AD patient and control cases. For each cas...
Western blot analysis of A brain-derived neurotrophic factor (BDNF), B Growth associated protein 43 ...
Table S3. List of novel proteins with altered abundances in AD identified in the present study. The ...
Table S2. GO Elite analysis of all 4,133 proteins identified in mouse microglia by TMT mass spectrom...
Table S1. Log2 transformed protein abundance data and differential expression analyses. (XLSX 1522 k...
Figure S4. TMT Network Modules Associated with Disease State or AD Pathology. (A-F) TMT network modu...
Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asympt...
Table S1. Sample List. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; M...
Table S1. iTRAQ quantified human brain proteome of AD individuals and their age-matched control. The...
Table S3. iTRAQ-quantified Mitochondrial proteins with log2 iTRAQ ratio. (XLSX 107 kb
Table S4. Proteins identified in purified mitochondria from each individuals. The data presented is ...
Table S2. iTRAQ quantified human brain proteome of AD individuals and their age-matched control with...
Table S4. Pathway analysis of proteins differentially increased in 5xFAD (vs. WT) microglia. (XLSX 1...
Figure S1. SDS-PAGE of Brain Homogenates. Dorsolateral prefrontal cortex (DLPFC) brain tissue homoge...
A. Percentage coefficient of variation of calculated iTRAQ ratios. Less than 5 % of protein ratios i...
Table S1. Demographic and neuropathological data of human AD patient and control cases. For each cas...
Western blot analysis of A brain-derived neurotrophic factor (BDNF), B Growth associated protein 43 ...
Table S3. List of novel proteins with altered abundances in AD identified in the present study. The ...
Table S2. GO Elite analysis of all 4,133 proteins identified in mouse microglia by TMT mass spectrom...
Table S1. Log2 transformed protein abundance data and differential expression analyses. (XLSX 1522 k...
Figure S4. TMT Network Modules Associated with Disease State or AD Pathology. (A-F) TMT network modu...
Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asympt...
Table S1. Sample List. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; M...